## Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 4

ACELRX PHARMACEUTI Form 4 July 28, 2014	CALS INC					
FORM 4 UNITED		RITIES AND EXCHANGE Ashington, D.C. 20549	COMMISSION		PPROVAL 3235-0287	
Section 16. Form 4 or Form 5 Filed pu	MENT OF CHAI rsuant to Section (a) of the Public U	NGES IN BENEFICIAL OV SECURITIES 16(a) of the Securities Exchar Jtility Holding Company Act nvestment Company Act of 1	nge Act of 1934, of 1935 or Section	Expires: Estimated a burden hou response	irs per	
(Print or Type Responses)						
1. Name and Address of Reporting EDWARDS MARK G	Symbol	er Name and Ticker or Trading RX PHARMACEUTICALS ACRX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) ( C/O ACELRX PHARMACEUTICALS, IN GALVESTON DRIVE	(Month/ 07/24/2	of Earliest Transaction Day/Year) 2014	X Director Officer (give below)		6 Owner er (specify	
(Street)	Filed(Me	endment, Date Original onth/Day/Year)	Applicable Line) _X_ Form filed by C	by One Reporting Person		
REDWOOD CITY, CA 940	63		Form filed by M Person	fore than One Ro	eporting	
(City) (State)	(Zip) Tal	ole I - Non-Derivative Securities A	cquired, Disposed of	, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price	SecuritiesFBeneficially(IOwned(I	. Ownership Form: Direct D) or Indirect I) Instr. 4)	Indirect	
Reminder: Report on a separate lin	e for each class of sec	urities beneficially owned directly o	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable a Date (Month/Day/Year)	and Expiration	7. Title and A Underlying S (Instr. 3 and -	Securit
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Stock Option (Right to Buy) (1)	\$ 10.22	07/24/2014		A	15,000	08/24/2014(2)(3)	07/23/2024	Common Stock	15,(

## Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director 10% Owner Offic		Officer	Other	
EDWARDS MARK G C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY, CA 94063	Х				
Signatures					
/s/ Christopher Whitmore, Attorney-in-fact	07/28/20	)14			
**Signature of Reporting Person	Date				
Evaluation of Decreases	-				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Issued pursuant to the 2011 Equity Incentive Plan
- (2) The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Optionee's Continuous Service on the Company's Board of Directors.
- (3) 100% Acceleration upon Change of Control.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.